Imugene (Australia) Odds of Future Stock Price Finishing Over 0.0386
| IMU Stock | 0.04 0 5.41% |
Imugene |
Imugene Target Price Odds to finish over 0.0386
The tendency of Imugene Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above 0.04 in 90 days |
| 0.04 | 90 days | 0.04 | about 98.0 |
Based on a normal probability distribution, the odds of Imugene to stay above 0.04 in 90 days from now is about 98.0 (This Imugene probability density function shows the probability of Imugene Stock to fall within a particular range of prices over 90 days) . Probability of Imugene price to stay between 0.04 and its current price of 0.039 at the end of the 90-day period is near 1 .
Assuming the 90 days trading horizon the stock has the beta coefficient of 1.07 . This usually indicates Imugene market returns are related to returns on the market. As the market goes up or down, Imugene is expected to follow. Additionally Imugene has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Imugene Price Density |
| Price |
Predictive Modules for Imugene
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Imugene. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Imugene Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Imugene is not an exception. The market had few large corrections towards the Imugene's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Imugene, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Imugene within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.49 | |
β | Beta against Dow Jones | 1.07 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | -0.12 |
Imugene Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Imugene for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Imugene can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Imugene generated a negative expected return over the last 90 days | |
| Imugene has some characteristics of a very speculative penny stock | |
| Imugene has high historical volatility and very poor performance | |
| Imugene has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 4.97 M. Net Loss for the year was (149.68 M) with profit before overhead, payroll, taxes, and interest of 11.78 M. | |
| Imugene has accumulated about 49.54 M in cash with (97.32 M) of positive cash flow from operations. | |
| Roughly 14.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: ASX Health Stocks Imugene reveals promise in lymphoma trial, stock soars 27pc - MSN |
Imugene Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Imugene Stock often depends not only on the future outlook of the current and potential Imugene's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Imugene's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 7.1 B | |
| Cash And Short Term Investments | 94.5 M |
Imugene Technical Analysis
Imugene's future price can be derived by breaking down and analyzing its technical indicators over time. Imugene Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Imugene. In general, you should focus on analyzing Imugene Stock price patterns and their correlations with different microeconomic environments and drivers.
Imugene Predictive Forecast Models
Imugene's time-series forecasting models is one of many Imugene's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Imugene's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Imugene
Checking the ongoing alerts about Imugene for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Imugene help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Imugene generated a negative expected return over the last 90 days | |
| Imugene has some characteristics of a very speculative penny stock | |
| Imugene has high historical volatility and very poor performance | |
| Imugene has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 4.97 M. Net Loss for the year was (149.68 M) with profit before overhead, payroll, taxes, and interest of 11.78 M. | |
| Imugene has accumulated about 49.54 M in cash with (97.32 M) of positive cash flow from operations. | |
| Roughly 14.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: ASX Health Stocks Imugene reveals promise in lymphoma trial, stock soars 27pc - MSN |
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.